Idioma:

Aprepitant and Fosaprepitant: A 10‐Year Review of Efficacy and Safety

Aapro, Matti ; Carides, Alexandra ; Rapoport, Bernardo L. ; Schmoll, Hans‐Joachim ; Zhang, Li ; Warr, David

The oncologist (Dayton, Ohio), 2015-04, Vol.20 (4), p.450-458 [Periódico revisado por pares]

Durham, NC, USA: AlphaMed Press

Texto completo disponível

Citações Citado por

Enviar para

Título:
Aprepitant and Fosaprepitant: A 10‐Year Review of Efficacy and Safety
Autor: Aapro, Matti ; Carides, Alexandra ; Rapoport, Bernardo L. ; Schmoll, Hans‐Joachim ; Zhang, Li ; Warr, David
Assuntos: Administration, Intravenous ; Administration, Oral ; Antiemetics - therapeutic use ; Antineoplastic Agents - adverse effects ; Aprepitant ; Chemotherapy‐induced nausea and vomiting ; Drug Interactions ; Fosaprepitant ; Guidelines as Topic ; Highly emetogenic chemotherapy ; Humans ; Moderately emetogenic chemotherapy ; Morpholines - therapeutic use ; Nausea - chemically induced ; Nausea - drug therapy ; Neurokinin‐1 receptor antagonist ; Stem Cell Transplantation ; Symptom Management and Supportive Care ; Vomiting - chemically induced ; Vomiting - drug therapy
É parte de: The oncologist (Dayton, Ohio), 2015-04, Vol.20 (4), p.450-458
Notas: Disclosures of potential conflicts of interest may be found at the end of this article.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Article-1
ObjectType-Feature-2
Descrição: Chemotherapy‐induced nausea and vomiting (CINV) is a common adverse event associated with anticancer treatment that can have a significant adverse impact on patient health‐related quality of life and that can potentially undermine the effectiveness of chemotherapy. Traditional regimens to prevent CINV generally involved a combination of a corticosteroid plus a 5‐hydroxytryptamine (5HT3) receptor antagonist (RA). In the past 10 years, antiemetic treatment has greatly advanced with the availability of the neurokinin‐1 receptor antagonist (NK1 RA) aprepitant and its prodrug fosaprepitant. NK1 RAs have a different mechanism of action in CINV than corticosteroids and 5HT3 RAs, thus their use can complement traditional antiemetic drugs and can enhance control of CINV. This review examined accumulated data regarding the safety and efficacy of aprepitant and fosaprepitant over the decade since the first regulatory approval. Data from key studies of aprepitant and fosaprepitant in the prevention of CINV in patients receiving moderately and highly emetogenic chemotherapy were explored, as were recommendations in currently available guidelines for their use. In addition, their use as antiemetic therapy in special patient populations was highlighted. Future perspectives on potential uses of aprepitant and fosaprepitant for indications other than CINV are presented. Aprepitant (and its prodrug fosaprepitant) is a neurokinin‐1 receptor antagonist approved more than a decade ago for the prevention of chemotherapy‐induced nausea and vomiting (CINV). This review examined safety and efficacy data for aprepitant and fosaprepitant and explored recommendations in current guidelines for their use. Future perspectives on potential uses of aprepitant and fosaprepitant for indications other than CINV are discussed.
Editor: Durham, NC, USA: AlphaMed Press
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Aprepitant and Fosaprepitant: A 10‐Year Review of Efficacy and Safety

Aapro, Matti ; Carides, Alexandra ; Rapoport, Bernardo L. ; Schmoll, Hans‐Joachim ; Zhang, Li ; Warr, David

Durham, NC, USA: AlphaMed Press

Buscando em bases de dados remotas. Favor aguardar.